pt
like range-bound prove drive growth
lower sale vs street ep unchd
vs street sale compound-annual-growth-rate driven ih off-set
eh declin ih need
reconsid split eh ih lose competit posit need drive
revenue/ep growth low-/mid-singl digit oncology/i ibrance/
xeljanz xr leader late io market growth off-set
biosimilar enbrel diseas enhanc tafamadi ripe bolt-on
 reiter hold/low pt ep
lower revenu top-lin growth need
lower sale vs street pfe
midpoint miss sale click maintain rang
despit increment fx tailwind ep unchang
vs street mid-point pfe rang model
pfe overal revenu compound-annual-growth-rate vs street solid
innov ih growth weigh essenti
eh declin face ep
compound-annual-growth-rate vs street mostli driven opex cost reduct share
repurchas think ih miss domin market-lead posit high-
growth area rel peer foundat strong oncolog
immunolog diseas platform think intern asset
spark acceler growth appear
bullish intern growth reiter call ih/eh split
tabl downplay need large-scal emphas
robust intern pipelin without large-scal expect
pfe sales/ep cagr rise meaning low-single/mid-singl digit
level maintain hold rate adjust pt
ep support dcf multipl line us
major pharma group seen turn multipl compress
sinc mid-march lack us-l deal volum deal ytd
ex-u buyer polit concern around drug price ahead
trump may speech click note entitl us biopharma trump
drug price speech look increas brand competit risk includ
overpay larg biopharma well clinic regulatori commerci
tr target
consist view strategi need
note repeatedli click quarterli preview note entitl preview- look
clariti consum strateg review strategi think need pursu
large-scal deal improv growth outlook innov ih brand busi
growth pfe ih busi crucial next five year look weather headwind
expect headwind
follow less per year consid oncolog must-win area
compani establish strong foothold market
lag behind io space expect top note preview
click tax reform price pressur alreadi driven announc biopharma
ytd deal valu eu/japanes pharma binari event lung
cancer io continu play click post-aacr note bristol-my
buy merck buy strateg think ih lose market-lead posit high-growth
therapeut area rel peer view pfe downplay transform interest
head fake simpli inconsist ceo histor appetit transform
follow bid astrazeneca azn rate allergan buy sinc earn
call click note entitl rais sale ep estim take center stage
comment would forefront industri consolid howev ceo
comment recent worth pay azn imposs target state
call see need transform deal see one appropri valu
right marketplac
strong breast/prost foothold far behind io
consid oncolog must-win area ibranc year advantag
market place domin leadership posit class howev think
late immuno-oncolog market multipl innov oncolog
asset pipelin think need larger chunk io pie truli enhanc oncolog
ibranc ibranc strong global sale growth yoy robust clinic develop plan
support thesi continu leverag first-mov advantag oral
market retain domin share howev brand face rise competit
eli lilli buy verzenio novarti nv rate kisqali particularli us
growth expect come ex-u geograph expans near-term focus
earli stage breast cancer bc tumor long-term note preview
click ibranc volum growth us appear taper gradual
vs note unspecifi impact custom buy
pattern ibranc us sale lli verzenio shown earli success market
us nbrx share approach six month launch ahead nv kisqali think
ibranc growth ex-u market expect come new/rec geograph launch
state decemb ibranc share countri ibranc
gain reimburs ex-u market includ japan posit robust
growth competit rise also robust on-going clinical-develop program ibranc
exclus us/eu/jp expect extens
aim expand ibranc early-stag breast cancer lucr market larger patient
popul metastat bc read-out three on-going clinic trial pallet penelope-
 palla expect year-end result pallet ibranc letrozol neoadjuv
bc expect fall remain confid probabl success base strong
result investigator-sponsor neopalana studi penelope-b palla studi
event-driven trial exact time unclear data like read-out model ibranc
sale vs street
bavencio/io combos/triplet merck kgaa mrk-de rate bavencio de
minimi player us io market latest share come click note entitl
io ket mom adj bmi opdivo share flat mrk keytruda lose think
bavencio struggl gain traction due focu nich opportun merkel cell carcinoma
 crowd bladder cancer indic see label bavencio fail show overal surviv os
page
benefit chemotherapi javelin lung tumor mid-februari third-lin
gastric cancer pivot phase javelin gastric trial click bavencio multipl
read-out out-year ovarian renal gastric lung bladder
ovarian bullish develop combo/triplet io backbon howev
recent failur epacadostat ido rais question use molecul monotherapi
respons combo click note entitl major pharma- bmi yervoy main beneficiari
inci ido failur melanoma model bavencio vs street
xtandi xtandi us sale yoy miss our/street estim
order re-acceler growth need drive robust uptak xtandi non-metastat
castration-resist prostat cancer nmcrpc set fda set juli pdufa date xtandi
snda nmcrpc base prosper trial result see high likelihood approv launch
howev johnson johnson rate launch next-gener androgen receptor
erleada apalutamid nmcrpc approv feb secur import first-to-market
advantag month stay jnj zytiga patent infring proceed expir octob
could lead indirect gener competit xtandi hamper growth howev
share call jan click note entitl result read-
across biopharma doesnt expect gener zytiga competit long-term
also look launch xtandi adjac prostat cancer indic non-metastat hormon
model xtandi sale vs street
pfe legaci oncolog asset sutent inlyta continu declin pipelin provid
upsid plan submit global regulatori file talazoparib parp base phase
embraca data click note entitl talazoparib impart month increment
benefit gbrca breast cancer gbrca breast cancer addit phase result
lorlatinib next-gen tyrosin kinas inhibitor nsclc share world lung
last year robust click note entitl major pharmaceut wlcl postview
 anticip fda action prioriti review august ema/jpmda decis
late also conduct phase crown studi head-to-head
studi compar lorlatinib xalkori alk nsclc patient final pfe dacomitinib also
undergo fda/ema review treatment egfr nsclc base head-to-head
studi vs azn iressa dacomitinib pdufa date sept
xeljanz xr growth off-set enbrel loe ex-u compound-annual-growth-rate
base market model expect global immunolog market grow
declin anti-tnf agent compound-annual-growth-rate off-set strong
growth next-gen oral biolog howev pfe immunolog inflamm franchis
xeljanz enbrel eucrisa expect declin compound-annual-growth-rate next five year put pressur
intern pipelin new use xeljanz/xr need improv growth outlook highli
support double-digit growth growth despit possibl rise competit class
off-set enbrel declin underwhelm eucrisa ramp model
vs street xeljanz/xr pfe lead jak inhibitor market allow establish
strong posit rheumatoid arthriti oral altern anti-tnf standard-of-car
ra patient refractori convent disease-modifi antirheumat drug cdmard
estim xeljanz us trx written tnf-nave patient strong
signal futur growth xeljanz approved/launch psoriat arthriti us
decemb march fda adcom back xeljanz xr ulcer coliti
vote increas chanc secur approv june pdufa
date expect indic contribut materi xeljanz sale growth out-year
outsid us xeljanz approv eu ra march chmp adopt posit
opinion xeljanz april model xeljanz sale vs street
outsid xeljanz howev busi struggl experienc slow uptak
eucrisa crisaborol topic inhibitor approv atop dermat us sale
fifth quarter launch qoq need find way re-acceler eucrisa
sale growth hope earn posit return acquisit anacor pharmaceut
model eucrisa sale vs street final enbrel declin
double-digit yoy ex-u market due biosimilar competit model
page
street note previous click postview note expect
immunolog franchis benefit next-gener jak-inhibitor pfe oral
inhibitor two on-going phase trial breakthrough therapi design
atop dermat first data expect
tafamadi enhanc commit diseas platform
pfe current diseas portfolio consist primarili older asset benefix refacto genotropin
etc declin major market howev sever intrigu
diseas asset pipelin note click note entitl tafamadi meglumin
meet primari endpoint orphan ttr cardiomyopathi diseas pfe tafamidi meglumin
achiev posit phase attr-act efficaci safeti result treatment patient
transthyretin cardiomyopathi ttr-cm ttr-cm rare diseas lead progress heart failur
pfe includ cardiomyopathi popul end spectrum wild-typ ttr
mutant ttr accord wild-typ repres bulk commerci opportun
competitor focus smaller mutant ttr popul receiv fda track
design develop ttr-cm expect share full phase result upcom
cardiovascular medic confer like european societi cardiolog esc vienna may
american heart associ aha chicago nov file fda
also develop rivipansel collabor
buy yatin suneja treatment vaso-occlus crisi voc associ sickl cell
diseas scd rivipansel pivot phase reset trial expect readout rivipansel
receiv orphan drug design fda ema fda also grant
track design bullish diseas busi call say think
critic mass diseas weve commit capit see diseas
therapeut area ripe bolt-on
eh impact slow biosimilar uptak sip shortag
declin pfe establish health eh busi continu sale
yoy model eh street
total revenu yield five-year compound-annual-growth-rate given weak eh busi rise
competit across number asset ih expect revisit discuss separ
ih eh busi shelv sept click note entitl split
innov health essenti health tabl expect near-term without transform
 cfo indic earn call split weve said previous
option take tabl forese futur never say never
anyth right forese futur execut busi
pfe eh busi expect experi sever one-tim sale up-tick follow signific
drag absorb declin peri-lo product per year ih busi
less addit think pfe eh busi
experienc price compress us outsid certain product emerg market pfe
two growth engin eh busi steril inject biosimilar steril inject
sip execut comprehens remedi plan resolv manufactur issu relat
legaci hospira busi result product shortag expect sip sale
roughli flat vs yoy expect addit capac sip
product avail lead busi back growth model sip sale
yoy street return growth model
sip sale compound-annual-growth-rate vs street biosimilar pfe biosimilar
portfolio repres key opportun growth eh franchis compound-annual-growth-rate although small
magnitud eh revenu total revenu make difficult segment
move needl compani whole plan launch five addit biosimilar
next two year pfe lead biosimilar inflectra biosimilar infliximab make gradual progress
share infliximab us volum climb end vs
pfe inflectra enjoy share veteran affair va abl
break substanti ground commerci insur even lower-pric due defens
contract practic howev europ share infliximab molecul
market outsid inflectra receiv complet respons letter fda
biosimilar herceptin trastuzumab relat technic issu efficacy/safety/
page
manufactur accord confid abl get product
approv launch within plan timelin
page
flow oper
yoy fx
fx
off-set dilut relat stock-comp
page
good sold
good sold
page
exhibit estim strh vs consensu
page
anticip global regulatori file talazoparib parp gbrca breast cancer base embraca
pdufa bosulif bosutinib ph cml prioriti review
expect fda action base prosper trial non-metastat prioriti review
pdufa ulcer coliti base result phase octav clinic trial
phase trial durat osteoarthr oa hip knee
pallet studi patient neoadjuv set
pdufa ask nsclc base result
pdufa egfr nsclc base archer studi result
ftf anda filer hikma could potenti launch gener abirateron end
result io triplet studi avelumab
expect ema action egfr nsclc base archer data accept apr
ema action psoriat arthriti
phase trial durat osteoarthr oa hip knee
phase long-term safeti trial osteoarthr oa hip knee
phase tango trial chronic lower back pain
ema jpmda action ema jpmda action ask nsclc base result
regulatori decis expect regulatori action talazoparib parp gbrca breast cancer base embraca
pivot javelin lung studi first line non-smal cell lung cancer nsclc
pivot javelin io chemo advanc malign
arch studi metastat hormon sensit prostat cancer mhspc
palla studi patient adjuv set
penelope-b studi patient hormon receptor posit normal residu diseas
complet pearl studi recurr breast cancer
embark studi non-metastat hormon sensit prostat cancer nmhspc
page
exhibit product strh vs consensu
sale
sale
page
exhibit product strh vs consensu
sale
sale
page
exhibit product strh vs consensu
sale
sale
page
exhibit product strh vs consensu
sale
sale
sale
sale
page
good sold
page
equival
prepaid expens
asset discontinu busi
net properti plant equip
long-term loan invest
liabil sharehold equiti
st debt current portion lt debt
liabil discontinu busi
defer tax tax
equiti attribut non-control interest
total liabil equiti
page
exhibit statement flow
depreci amort
gain sale equiti invest
loss gain sale busi
chang work capit
purchas short-term invest
proce short-term sale invest
purchas long-term invest
proce redempt long-term invest
purchas asset
proce sale asset
purchas busi
proce sale busi
proce issuanc long-term debt
repay long-term debt
increas short-term debt
decreas short-term debt
purchas common stock
discontinu oper
effect exchang rate
cash/equival begin period
cash/equival end period
page
global biopharmaceut compani focus drug discoveri develop
commerci pfe total sale sale evenli divid
us ex-u market pfe innov health ih brand busi account
total net sale ih hous intern medicin vaccin oncolog inflamm immunolog
sale brand ih busi compris lyrica neuropath pain fibromyalgia
pneumococc vaccin sever oncolog asset ibranc xtandi sutent inlyta
xalkori pfe franchis compris enbrel xeljanz eucrisa
pfe establish health eh gener busi account sale legaci
establish product account eh sale steril inject pharmaceut peri-
loe product infus system divest center-on biosimilar repres
 respect eh busi compris erstwhil blockbust product
lipitor premarin norvasc epipen celebrex xalatan viagra zithromax effexor xanax zoloft
relpax etc robust biosimilar pipelin account sale sourc
hospira acquisit biosimilar molecul clinic develop
rate hold base long-term growth outlook sales/ep cagr lowest
amongst peer group sales/ep growth vs street
pfe innov health busi crucial top-lin growth next five year look
weather combin across busi given expect challeng us
volum /gross-to-net sale trend matur product recent forthcom loss exclus
eh busi lyrica eu enbrel eu/jp zyvox us relpax us/eu tygacil us/eu viagra
 rapamun eu pfe top-lin growth hing limit number intern develop brand
growth driver across intern medicin lyrica us chantix us oncolog ibranc xtandi
 xeljanz/xr eucrisa franchis number ih franchis face competit headwind
includ prevnar lyrica gener competit eu loe enbrel ex-u biosimilar competit
oncolog competit xalkori roche/novartis/oth inlyta/sut renal cell carcinoma
opdivo advers impact perform
oncolog late immuno-oncolog io market bavencio fifth entrant
crowd io market bullish doublet triplet io combo therapi although toxic
cost consider temper enthusiasm competit space rise
verzenio abemaciclib kisqali launch place downward pressur ibranc trajectori
addit pfe eh segment see global price competit especi us gener
price declin mid-to-high teen rate attempt mitig risk aggress
price increas biosimilar portfolio asset goal five biosimilar
regulatori file note biolog eros legal hurdl high bar biosimilar
interchang stifl growth
need biosimilar portfolio along steril inject minim declin
legaci eh product peri-lo product account essenti health sale result
busi pressur done tuck-in acquisit hospira anacor mediv
howev expect bolt-on large-scal transform deal improv long-
term growth rate re-consid split ih eh busi abandon
septemb
valuat risk
arriv target price assum stock trade ep believ
in-lin multipl compar peer group averag warrant due pfe anem growth outlook
higher concentr sale gener eh account sale view stock
range-bound sinc manag demonstr lack urgenc wait macro
factor us tax reform and/or repatri ii binari event io clinic trial
could materi alter valuat potenti target time pfe dividend yield
page
aggress share repurchas add floor stock view dcf analysi yield intrins
valu per share
risk thesi includ increas competit key growth product ibranc
xalkori inlyta sutent xtandi xeljanz bavencio price pressures/high discount rebat
demand payer govern greater expect gener price compress
legaci eh product peri-lo addit risk overpay larg
biopharma acquisit convers also note sourc posit risk could includ earlier
expect transform drive sharehold return better expect perform
growth asset instanc eliqui posit blood thin market could add signific
upsid pfe allianc revenu xtandi could receiv boost sale perform
non-metastat segment prostat cancer market
compani mention note
compani buy john bori
astrazeneca plc azn rate
novarti ag nv rate
merck kgaa mrk-de rate
johnson johnson rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
